|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Short-term investments | ||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||
| Inventories | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Current assets held for sale | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Restricted time deposits | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Finance lease right-of-use assets | ||||||||||||||||||||
| Equity method investment in unconsolidated variable interest entity | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Long-term investments | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Long-term assets held for sale | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities, redeemable non-controlling interests and deficit | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued and other current liabilities | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Finance lease liabilities, current | ||||||||||||||||||||
| Senior secured term loan facilities, current | ||||||||||||||||||||
| Current liabilities held for sale | ||||||||||||||||||||
| Operating lease liabilities, current | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Product development obligations | ||||||||||||||||||||
| Deferred revenue, net of current | ||||||||||||||||||||
| Finance lease liabilities, non-current | ||||||||||||||||||||
| Operating lease liabilities, non-current | ||||||||||||||||||||
| Senior secured term loan facilities, non-current | ||||||||||||||||||||
| Liability related to sale of future revenues, non-current | ||||||||||||||||||||
| Other long-term liabilities | ||||||||||||||||||||
| Long-term liabilities held for sale | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Redeemable non-controlling interests | ||||||||||||||||||||
| Stockholders' deficit: | ||||||||||||||||||||
| Common stock, $0.01 par value; 225,000 shares authorized at June 30, 2026 and December 31, 2025; 4,049 and 4,047 shares issued and outstanding at June 30, 2026 and December 31, 2025 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders' deficit attributable to Kyntra Bio | ||||||||||||||||||||
| Nonredeemable non-controlling interests | ||||||||||||||||||||
| Total deficit | ||||||||||||||||||||
| Total liabilities, redeemable non-controlling interests and deficit | ||||||||||||||||||||
Loading...
